The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Venlafaxine ER as a Treatment for Generalized Anxiety Disorder in Older Adults: Pooled Analysis of Five Randomized Placebo‐Controlled Clinical Trials
Abstract
OBJECTIVES: Concerns about the safety of benzodiazepines in older adults may have led investigators and clinicians to underestimate the importance of adequately treating generalized anxiety disorder (GAD) in later life. To evaluate the safety and efficacy profile of an alternative treatment in older patients, we conducted a secondary analysis of five randomized, placebo‐controlled clinical trials of extended release venlafaxine (venlafaxine ER, Effexor XR ® ) for adult patients with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM‐IV) diagnosis of GAD. DESIGN: The five multicenter, parallel‐group, double‐blind, prospectively randomized, placebo‐controlled clinical trials used similar designs to evaluate short‐term efficacy after 8 weeks. In addition, two studies evaluated efficacy and safety over 24 weeks under double‐blind conditions. SETTING: Outpatients from both primary care and specialty mental healthcare settings were included. Three studies were conducted in the United States and two in Europe. PARTICIPANTS: Intention‐to‐treat analyses included 1,839 adult outpatients with a DSM‐IV diagnosis of GAD and total scores of ≥18 on the Hamilton Rating Scale for Anxiety (HAMA). Ten percent of the patients were aged 60 and older and 5.0% were aged 65 and older. INTERVENTION: Fixed or flexible doses of venlafaxine ER in the dose range of 37.5 to 225 mg/day or matched placebo were used for 8 weeks in all studies and for 24 weeks in two studies. MEASUREMENTS: Primary efficacy variables included the HAMA total score and psychic anxiety factor, the anxiety subscale of the Hospital Anxiety and Depression (HAD) Scale, and the Clinical Global Impression of Improvement (CGI‐I). Secondary efficacy variables included the HAMA somatic anxiety factor, the depression subscale of the HAD, CGI‐3 severity, the Covi Scale for Anxiety, and the Raskin Scale for Depression. RESULTS: On the CGI, 66% of older patients (≥60 years) responded to venlafaxine ER, compared with 41% for placebo ( P < .01 by logistic regression). For younger patients (<60 years), comparable figures were 67% and 44%, respectively ( P < .001). Analysis of variance showed no main effects for age and no age‐by‐treatment interactions for any of the primary or secondary efficacy outcome measures for either the 8‐ or 24‐week analyses. Within the older adults subgroup, increasing age did not influence responses. In this cohort of GAD patients, higher levels of depression were associated with decreased responses of anxiety symptoms. In older adults, 23% of venlafaxine ER patients discontinued treatment prematurely versus 31% of those who received placebo; comparable figures for younger adult patients were 27% and 28%, respectively. Discontinuations due to adverse events were 15% versus 14% for venlafaxine ER and placebo, respectively, in older adults compared with 15% versus 8%, respectively, for younger adults. CONCLUSION: Venlafaxine ER is equally safe and well tolerated by and shows similar efficacy in younger and older patients in the treatment of GAD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
de BEURS, E., BEEKMAN, A. T. F., van BALKOM, A. J. L. M., DEEG, D. J. H., van DYCK, R., & van TILBURG, W. (1999) · Psychological Medicine · doi:10.1017/s0033291799008351 · Cited by 378
Treatment outcomes for primary care patients with major depression and lifetime anxiety disorders.
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.10.1293 · Cited by 312
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Anxiety disorders in older adults: a comprehensive review
Wolitzky-Taylor, K. B., Castriotta, N., Lenze, E. J., Stanley, M. A., & Craske, M. G. (2010) · Depression and Anxiety · doi:10.1002/da.20653 · Cited by 726
“Citalopram,([82]) sertraline,([155]) and venlafaxine ER([156]) have all demonstrated efficacy for reducing anxiety among elderly patients.”
BackgroundBaldwin, D. S., Anderson, I. M., Nutt, D. J., Bandelow, B., Bond, A., Davidson, J. R. T., den Boer, J. A., Fineberg, N. A., Knapp, M., Scott, J., et al. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105059253 · Cited by 617
Yatham, L. N., Kennedy, S. H., O'Donovan, C., Parikh, S., MacQueen, G., McIntyre, R., Sharma, V., Silverstone, P., Alda, M., Baruch, P., et al. (2005) · Bipolar Disorders · doi:10.1111/j.1399-5618.2005.00219.x · Cited by 388
Metadata
- Authors
- Katz, I. R., Reynolds, C. F., Alexopoulos, G. S., & Hackett, D.
- Venue
- Journal of the American Geriatrics Society
- Publisher
- Wiley
- Published
- 2002-01
- Volume
- 50
- Issue
- 1
- Pages
- 18-25
- ISSN
- 0002-8614 (ISSN-L)
- 1532-5415
- OpenAlex
- W1996297708
- Cited by
- 158
- References
- 2
- FWCI
- 18.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Venlafaxine ER as a Treatment for Generalized Anxiety Disorder in Older Adults: Pooled Analysis of Five Randomized Placebo‐Controlled Clinical Trials. https://app.cochat.ai/papers/10.1046/j.1532-5415.2002.50003.x
- The paper
- Katz, I. R., Reynolds, C. F., Alexopoulos, G. S., & Hackett, D. (2002). Venlafaxine ER as a Treatment for Generalized Anxiety Disorder in Older Adults: Pooled Analysis of Five Randomized Placebo‐Controlled Clinical Trials. Journal of the American Geriatrics Society. https://doi.org/10.1046/j.1532-5415.2002.50003.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.